- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Risankizumab – July 2019
Risankizumab : Injection 75 mg in 0.83 mL pre-filled syringe; Skyrizi®
Last updated
6 March 2020